| 1 | Immunosuppression and immunotherapy in endometriosis: review of pathophysiology, recent development and future perspectives He Y, Hung KSW, Xu H, Wang CC In: Immunology of Endometriosis: Pathogenesis and Management 2021; Volume 2 Ch 18: 271-296 |
| 2 | An In-Silico, In-Vitro and In-Vivo Combined approach to identify NMNATs as potential protein targets of ProEGCG for treatment of endometriosis Hung SW, Liang B, Gao Y, Zhang R, Tan Z, Zhang T, Chung PWJ, Chan TH, Wang CC Front Pharmacol. 2021 Oct 14;12:714790 |
| 3 | Receptor tyrosine kinase inhibitor Sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis He Y, Hung SW, Liang B, Zhang RZ, Gao YT, Chu CY, Xu H, Zhang T, Chung JPW, Wang CC Front. Immunol. 2021 July;12:641206 |
| 4 | Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review Hung SW, Zhang RZ, Tan ZYR, Chung JPW, Zhang T, Wang CC Med Res Rev. 2021 Jul;41(4):2489-2564 |
| 5 | A polysaccharide extract from the medicinal plant Maidong inhibits the IKK–NF-κB pathway and IL-1β–induced islet inflammationand increases insulin secretion Mao DD, Tian XY, Mao D, Hung SW, Wang CC, Lau CBS, Lee HM, Wong CK, Chow E, Xing M, Cao HY, Ma RCW, Chan PKS, Kong APS, Li JJX, Rutter G, Tam WH, Chan JCN J Biol Chem. 2020 Sep 4;295(36):12573-12587 |